CCRB Logo

Trial History Detail on 2009-11-19

CUHK_CCT00165

2008-07-11

Prospective

NIL

Joint Shantou International Eye Center, Shantou, Guangdong Province, China

Professor Nathan Congdon, Department of Ophthalmology and Visual Science

Professor Zhang Mingzhi, Director of Joint Shantou International Eye Center

Nathan Congdon

7/F, Block B, Department of Ophthalmology and Visual Science,Prince of Wales Hospital, Shatin NT

Phone: +852 6113 4445

Email: NCONGDON@CUHK.EDU.HK ,

Nathan Congdon

7/F, Block B, Department of Ophthalmology and Visual Science,Prince of Wales Hospital, Shatin NT

Phone: +852 6113 4445

Email: NCONGDON@CUHK.EDU.HK ,

Randomized, Short-term Trial of Gingko Biloba in the Treatment of Normal Tension and High-Tension Glaucoma

NIL

Yes

2008-05-16

Normal Tension Glaucoma, High Tension Glaucoma

Drug

Gingko Biloba 240mg QD

Eight weeks

Placebo - Calcium tablets

Inclusion Criteria: A. Definite glaucomatous VF (at least three contiguous points in one hemi-field abnormal below the 1% level, two of which are observed on three successive VF tests) and disc damage (CDR >= 0.7 and/or a rim width of <= 0.1 in at least one quadrant, as graded by a glaucoma specialist) in at least one eye. B. For NTG: Average of two highest readings on 12-hour IOP testing off of any ocular hypertensive treatment are <= 18 mmHg C. For pressure-dependent glaucoma: Documented IOP >= 22 mmHg on at least two occasions

Exclusion Criteria: a. Any history of dementia or other cognitive abnormality, or evidence on examination or history of non-ocular causes for VF loss. b. Any evidence of disc pallor, retinal abnormality or other finding on ocular examination to suggest an ocular cause other than glaucoma for the VF loss or disc abnormality. c. Need for surgical intervention of any kind, or change in medication within one month of initiating participation in the study.

Randomized

Placebo

Double-blind

Crossover

2008-07-18

60

Not Yet Recruiting

a. Visual field: MD, CPSD, and change in these two parameters before and after treatment over 8 weeks. b. Optic nerve blood flow, and change before and after treatment over 8 weeks. c. Visual function and change before and after treatment d. Effect of treatment type (GBE versus placebo) on the three above parameters e. Effect of glaucoma type (NTG versus pressure-dependent) on changes in VF, visual function and blood flow parameters

f. Change in effect on blood flow, visual function and VF parameters with continued treatment over time with GBE (total of 8 months after cessation of randomized therapy)

No

2013-05-06


Yes

Type Access Document Published On  
No documents yet.
  • Page 1 of 1.